A Phase 1 Study to Evaluate the Impact of CYP3A4 Induction on the Single Dose Pharmacokinetics of ALKS 5461

Trial Profile

A Phase 1 Study to Evaluate the Impact of CYP3A4 Induction on the Single Dose Pharmacokinetics of ALKS 5461

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Nov 2015

At a glance

  • Drugs Buprenorphine/samidorphan (Primary) ; Rifampicin
  • Indications Cocaine abuse; Kidney disorders; Major depressive disorder
  • Focus Pharmacokinetics
  • Sponsors Alkermes plc
  • Most Recent Events

    • 09 Nov 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 15 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top